NovoCure (NVCR) Cost of Revenue (2014 - 2026)

NovoCure's Cost of Revenue history runs 13 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 1.06% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at $150.0 million (up 102.52% YoY), while the FY2025 annual figure was $166.9 million, up 21.65% from the prior year.
• Cost of Revenue came in at $38.9 million for Q1 2026 at NovoCure, up from -$4.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $58.5 million in Q3 2025 to a low of -$39.3 million in Q4 2023.
• A 5-year average of $25.9 million and a median of $33.7 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue slumped 236.18% in 2023 and jumped 86.87% in 2025, its largest moves.
• NovoCure's Cost of Revenue stood at $28.9 million in 2022, then plunged by 236.18% to -$39.3 million in 2023, then advanced by 12.38% to -$34.5 million in 2024, then surged by 86.87% to -$4.5 million in 2025, then jumped by 960.31% to $38.9 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $38.9 million, -$4.5 million, and $58.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison